<DOC>
	<DOCNO>NCT01185938</DOCNO>
	<brief_summary>This open-label study , prospective , randomized trial evaluate acute ( in-hospital ) pleiotropic clinical effect hydrophilic statin ( rosuvastatin ) patient acute coronary syndrome</brief_summary>
	<brief_title>Statin Contrast Induced Nephropathy Prevention</brief_title>
	<detailed_description>The primary purpose study determine whether , patient acute coronary syndrome take statin chronic administration , high dos hydrophilic statin ( rosuvastatin ) administer coronary angiography and/or angioplasty , may exert renal-protective effect reduce incidence contrast nephropathy . Contrast induce nephropathy define increased value creatinine &gt; = 0.3 mg/dl baseline value , within 72 hour contrast medium exposure . Secondary end point : 1 ) verify short-term ( &lt; 48 hour ) statin administration reduces peak level curve area marker myocardial necrosis throughout hospitalization period reduces occurrence periprocedural infarction . Biochemical marker ( quantitative creatine kinase-MB ( CK-MB ) mass Troponin I ) measure admission 6 , 12 , 24 hour first day daily , immediately angiography , 24 hour thereafter . In patient underwent coronary angioplasty ( PCI ) , biochemical marker measure 12 24 hour procedure . Data fit , peak value curve area calculate ; occurrence periprocedural infarction define CK-MB mass elevation three time upper limit normal within 24 hour PCI . 2 ) determine distribution peripheral lymphocytic population entry discharge use flow cytometric analysis ; 3 ) analyze clinical composite outcome death , myocardial infarction , urgent revascularization , dialysis stroke 30 day 6 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Are eligible study patient admit CCU Acute Coronary Syndrome without ST elevation ( NSTEMI ) candidate early invasive strategy ( coronary angiography within 48 hour admission ) without previous therapy statin . 1. inability provide consent 2. pregnancy lactation 3. intolerance statin 4. therapy lipid lower drug 5. acute chronic liver disease 6. chronic muscle disease 7. acute renal failure chronic renal failure stage IV 8. neoplastic 9. exposure iodinate contrast medium previous 10 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>statin</keyword>
	<keyword>CIN</keyword>
	<keyword>periprocedural damage</keyword>
</DOC>